297 related articles for article (PubMed ID: 31754997)
1. The Role of Xenobiotics and Trace Metals in Parkinson's Disease.
Bjørklund G; Dadar M; Chirumbolo S; Aaseth J
Mol Neurobiol; 2020 Mar; 57(3):1405-1417. PubMed ID: 31754997
[TBL] [Abstract][Full Text] [Related]
2. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
Perfeito R; Cunha-Oliveira T; Rego AC
Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
[TBL] [Abstract][Full Text] [Related]
3. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
[TBL] [Abstract][Full Text] [Related]
4. Iron and other metals in the pathogenesis of Parkinson's disease: Toxic effects and possible detoxification.
Bjørklund G; Hofer T; Nurchi VM; Aaseth J
J Inorg Biochem; 2019 Oct; 199():110717. PubMed ID: 31369907
[TBL] [Abstract][Full Text] [Related]
5. Neuronal vulnerability in Parkinson's disease.
Double KL
Parkinsonism Relat Disord; 2012 Jan; 18 Suppl 1():S52-4. PubMed ID: 22166454
[TBL] [Abstract][Full Text] [Related]
6. The Overcrowded Crossroads: Mitochondria, Alpha-Synuclein, and the Endo-Lysosomal System Interaction in Parkinson's Disease.
Lin KJ; Lin KL; Chen SD; Liou CW; Chuang YC; Lin HY; Lin TK
Int J Mol Sci; 2019 Oct; 20(21):. PubMed ID: 31731450
[TBL] [Abstract][Full Text] [Related]
7. Mitochondrial iron dyshomeostasis and its potential as a therapeutic target for Parkinson's disease.
Xiao Z; Wang X; Pan X; Xie J; Xu H
Exp Neurol; 2024 Feb; 372():114614. PubMed ID: 38007207
[TBL] [Abstract][Full Text] [Related]
8. The centrality of mitochondria in the pathogenesis and treatment of Parkinson's disease.
Camilleri A; Vassallo N
CNS Neurosci Ther; 2014 Jul; 20(7):591-602. PubMed ID: 24703487
[TBL] [Abstract][Full Text] [Related]
9. Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson's disease.
Burbulla LF; Song P; Mazzulli JR; Zampese E; Wong YC; Jeon S; Santos DP; Blanz J; Obermaier CD; Strojny C; Savas JN; Kiskinis E; Zhuang X; Krüger R; Surmeier DJ; Krainc D
Science; 2017 Sep; 357(6357):1255-1261. PubMed ID: 28882997
[TBL] [Abstract][Full Text] [Related]
10. Determinants of dopaminergic neuron loss in Parkinson's disease.
Surmeier DJ
FEBS J; 2018 Oct; 285(19):3657-3668. PubMed ID: 30028088
[TBL] [Abstract][Full Text] [Related]
11. Current perspective of mitochondrial biology in Parkinson's disease.
Ammal Kaidery N; Thomas B
Neurochem Int; 2018 Jul; 117():91-113. PubMed ID: 29550604
[TBL] [Abstract][Full Text] [Related]
12. The role of alpha-synuclein in the development of the dopaminergic neurons in the substantia nigra and ventral tegmental area.
Tarasova TV; Lytkina OA; Roman AY; Bachurin SO; Ustyugov AA
Dokl Biol Sci; 2016; 466():5-7. PubMed ID: 27021360
[TBL] [Abstract][Full Text] [Related]
13. Mutant α-Synuclein Overexpression Induces Stressless Pacemaking in Vagal Motoneurons at Risk in Parkinson's Disease.
Lasser-Katz E; Simchovitz A; Chiu WH; Oertel WH; Sharon R; Soreq H; Roeper J; Goldberg JA
J Neurosci; 2017 Jan; 37(1):47-57. PubMed ID: 28053029
[TBL] [Abstract][Full Text] [Related]
14. Cholesterol contributes to dopamine-neuronal loss in MPTP mouse model of Parkinson's disease: Involvement of mitochondrial dysfunctions and oxidative stress.
Paul R; Choudhury A; Kumar S; Giri A; Sandhir R; Borah A
PLoS One; 2017; 12(2):e0171285. PubMed ID: 28170429
[TBL] [Abstract][Full Text] [Related]
15. Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson's disease.
Büeler H
Exp Neurol; 2009 Aug; 218(2):235-46. PubMed ID: 19303005
[TBL] [Abstract][Full Text] [Related]
16. Mitochondrial control of cell bioenergetics in Parkinson's disease.
Requejo-Aguilar R; Bolaños JP
Free Radic Biol Med; 2016 Nov; 100():123-137. PubMed ID: 27091692
[TBL] [Abstract][Full Text] [Related]
17. Ubiquinone (coenzyme q10) and mitochondria in oxidative stress of parkinson's disease.
Ebadi M; Govitrapong P; Sharma S; Muralikrishnan D; Shavali S; Pellett L; Schafer R; Albano C; Eken J
Biol Signals Recept; 2001; 10(3-4):224-53. PubMed ID: 11351130
[TBL] [Abstract][Full Text] [Related]
18. The role of dopamine in the pathogenesis of GBA1-linked Parkinson's disease.
Burbulla LF; Krainc D
Neurobiol Dis; 2019 Dec; 132():104545. PubMed ID: 31351996
[TBL] [Abstract][Full Text] [Related]
19. ER Stress Induced by Tunicamycin Triggers α-Synuclein Oligomerization, Dopaminergic Neurons Death and Locomotor Impairment: a New Model of Parkinson's Disease.
Cóppola-Segovia V; Cavarsan C; Maia FG; Ferraz AC; Nakao LS; Lima MM; Zanata SM
Mol Neurobiol; 2017 Oct; 54(8):5798-5806. PubMed ID: 27660269
[TBL] [Abstract][Full Text] [Related]
20. Converging roles of ion channels, calcium, metabolic stress, and activity pattern of Substantia nigra dopaminergic neurons in health and Parkinson's disease.
Duda J; Pötschke C; Liss B
J Neurochem; 2016 Oct; 139 Suppl 1(Suppl Suppl 1):156-178. PubMed ID: 26865375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
